GCG and Hyperglycemia: Given that increased glucagon secretion during DKA contributes to metabolic deterioration alongside insulin deficiency, therapeutic strategies targeting hyperglucagonemia—rather than focusing solely on hyperglycemia and insulin replacement—may offer additional clinical benefit.